Clinical development and current role of margetuximab for the treatment of breast cancer.

Abstract

Up to 20% of breast cancers overexpress HER2, a molecular alteration conferring these tumors a particularly aggressive behavior. However, targeting HER2 has radically changed the prognosis of this disease in the last 2 decades, with multiple anti-HER2 compounds shown to improve disease outcomes both in the early and advanced setting. The latest anti-HER2 compound to be approved by the U.S. Food and Drug Administration (FDA) was margetuximab, an Fc-engineered monoclonal antibody with an improved binding to FcγRIIIA receptor, which leads to a greater antibody-dependent cellular cytotoxicity (ADCC) activation compared with trastuzumab. Margetuximab was shown to slightly improve progression-free survival compared with trastuzumab when combined with chemotherapy for the treatment of advanced HER2-positive breast cancer patients, and is now included among the available treatment options for pretreated HER2-positive breast cancer patients. In this monograph we recapitulate the clinical development, current role and future perspectives of margetuximab for the treatment of breast cancer.

• Authors: P Tarantino, J Uliano, S Morganti, F Giugliano, E Crimini, G Curigliano
• Journal: Drugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 57 Issue 9 Pg. 551-558 (Sep 2021) ISSN: 1699-3993 [Print] Spain
• PMID: 34586103 (Publication Type: Journal Article)
• Copyright: Copyright 2021 Clarivate Analytics.

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Receptor, ErbB-2
• margetuximab
• Trastuzumab

Topics

• Antibodies, Monoclonal (adverse effects)
• Antibodies, Monoclonal, Humanized
• Breast Neoplasms (drug therapy)
• Female
• Humans
• Receptor, ErbB-2
• Trastuzumab